About Inhibrx
Inhibrx is a biotechnology company that specializes in developing therapeutic candidates using its proprietary single-domain antibody platform. The company's protein-engineering expertise has enabled it to create a unique pipeline of drugs that have the potential to revolutionize the treatment of various diseases.
The company's single-domain antibody platform is based on the use of small, stable, and highly specific antibodies that can target disease-causing proteins with high precision. These antibodies are derived from naturally occurring antibodies found in camelids, which have been engineered to improve their stability and specificity.
Inhibrx's pipeline includes several promising drug candidates that are currently undergoing clinical trials. One such candidate is INBRX-101, a treatment for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling in various parts of the body. INBRX-101 works by inhibiting plasma kallikrein, an enzyme involved in the production of bradykinin, which causes swelling in HAE patients.
Another drug candidate in Inhibrx's pipeline is INBRX-109, a treatment for solid tumors that overexpress T-cell immunoglobulin and mucin domain 3 (TIM-3). TIM-3 is an immune checkpoint protein that suppresses T-cell activity and promotes tumor growth. By blocking TIM-3 with INBRX-109, Inhibrx hopes to unleash the patient's immune system against cancer cells.
In addition to its drug development efforts, Inhibrx also offers its protein-engineering expertise as a service to other companies. Its team of scientists can design and optimize proteins for various applications such as diagnostics or industrial enzymes.
Overall, Inhibrx is poised to make significant contributions to the field of biotechnology with its innovative approach to drug development and protein engineering. Its unique pipeline of therapeutic candidates holds great promise for improving patient outcomes across multiple disease areas.